-
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
•
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business, marking a significant milestone in the French pharmaceutical giant’s strategic realignment. While no decision has been finalized, Sanofi will provide further updates…
-
Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal
•
French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers for its consumer health care (CHC) division, from private equity firms Clayton Dubilier & Rice and PAI Partners, according to sources cited by Bloomberg. The potential deal could value the business at up to EUR…
-
Altamira Therapeutics and Nuance Pharma Expand Bentrio’s Reach in Asia
•
Swiss pharmaceutical firm Altamira Therapeutics Ltd (NASDAQ: CYTO) and its Chinese partner Nuance Pharma have announced an expansion of their licensing agreement for the anti-rhinitis spray Bentrio. The agreement extends the product’s reach to include Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, and Taiwan, complementing the existing markets of China,…
-
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
•
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement with Shanghai Pharma Health Science, a subsidiary of Shanghai Pharmaceutical Group (SHA: 601607). The contract covers the distribution of seven OTC medications, which are planned to be initially marketed through Shanghai Pharma’s e-commerce platform, prior…
-
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
•
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first half of 2024. The company recorded a modest year-on-year (YOY) increase in revenue, reaching RMB 1.323 billion, which is a 2.5% uptick. More impressively, the adjusted net profit saw a substantial surge of 395.0% YOY,…
-
Beijing Proposes New Regulations to Enhance Pharmaceutical Retail Standards and Services
•
The Beijing Municipal Medical Products Administration has unveiled a draft proposal titled “Guiding Opinions on Further Strengthening the Standardized Management of Pharmaceutical Retail Enterprises and Improving the Quality of Pharmaceutical Services,” inviting public feedback until September 12, 2024. The proposal outlines several key initiatives aimed at enhancing the management and…
-
Yixintang Partners with Huawei Cloud to Drive Digital Transformation in Pharma Retail
•
Yixintang Pharmaceutical Group Co., Ltd. (SHE: 002727), a prominent pharmaceutical retail chain in China, has entered into a strategic partnership with telecom giant Huawei Cloud. The collaboration aims to enhance information infrastructure, develop data-enabled platforms, and innovate within the burgeoning health industry, all while driving the digital and intelligent transformation…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
-
Genrix Bio Pharmaceutical Partners with China Resource Medicine for Expanded Market Coverage
•
Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a strategic partnership with China Resource Medicine Commercial Holdings Ltd. The collaboration aims to enhance channel management and strengthen presence in the healthcare and retail markets. Financial details of the agreement were not disclosed. By…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency
•
Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has entered into a strategic partnership with Finland-based retail technology platform RELEX Solutions. Through the adoption of RELEX’s advanced forecasting and replenishment solutions, Deshengtang aims to optimize its end-to-end supply chain operations, rectify inventory structures, and…
-
Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million
•
Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to fully acquire Chongqing Hongrui Lebang Renjia Pharmacy Chain Co., Ltd for a consideration of RMB 167.8 million (USD 23.5 million). With this acquisition, Hongrui Lebang, a local drug retailer operating 190 drugstores, will become a…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing
•
China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon (NYSE: OGN) during the 6th China International Import Expo (CIIE) in Shanghai. The collaboration is centered around Organon’s Remeron (mirtazapine), with Qingyun playing a role in implementing omnichannel marketing strategies for the drug. Mirtazapine’s Mechanism…
-
ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions
•
Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550), focusing on the digestive enzyme field. The collaboration aims to explore and promote product development in the digestive tract health sector, with no financial details disclosed. Focus on Digestive Tract Health and…
-
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
•
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023, showing a 1% year-on-year (YOY) decrease in sales to USD 1.519 billion in constant currency terms. The company’s performance was marked by a 7% decline in Women’s Health sales to USD 418 million, a 10%…
-
Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products
•
UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic acquisition of four central nervous system (CNS) products from French pharmaceutical giant Sanofi (NASDAQ: SNY). This move signifies Pharmanovia’s commitment to enhancing its neurology offerings and aligns with Sanofi’s strategy to divest its Consumer Health…
